Paragon 28, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Form 4: Paragon 28, Inc. Officer Reports Disposition of Shares and Derivative Securities Following Merger
Robert S. McCormack, General Counsel and Corporate Secretary of Paragon 28, Inc., reports the disposition of common stock and performance stock units due to the merger with Zimmer Biomet Holdings, Inc.
Form 4: Paragon 28, Inc. Director Meghan Scanlon Reports Disposal of Shares in Merger with Zimmer Biomet
Meghan Scanlon, a director of Paragon 28, Inc., reported the disposal of 42,113 shares of common stock due to the merger with Zimmer Biomet Holdings, Inc.
Thomas Schnettler, a director at Paragon 28, reports the disposal of common stock due to the merger with Zimmer Biomet, receiving cash and contingent value rights.
Stephen Oesterle, a director of Paragon 28, reports the disposition of common stock and stock options due to the merger with Zimmer Biomet Holdings, Inc.
Director B. Kristine Johnson reports the disposal of Paragon 28 shares following the company's merger with Zimmer Biomet, receiving cash and contingent value rights in exchange.
Matthew Jarboe, Chief Commercial Officer of Paragon 28, reports the disposition of common stock, performance stock units, and stock options due to the merger with Zimmer Biomet Holdings, Inc.
EVP of Research & Development at Paragon 28, Andrew James Hill, reports the disposal of shares and performance stock units following the merger with Zimmer Biomet Holdings, Inc.
Form 4: Paragon 28 Director Blackford Reports Disposal of Shares Following Merger with Zimmer Biomet
Director Quentin S. Blackford reports the disposal of Paragon 28 shares due to the merger with Zimmer Biomet Holdings, Inc., where each share was converted into cash and a contingent value right.
Form 4: Paragon 28 Director Kristina Wright Reports Disposal of Shares Following Merger with Zimmer Biomet
Kristina Wright, a director at Paragon 28, reported the disposal of common stock due to the merger with Zimmer Biomet, where each share was converted into cash and a contingent value right.
Chadi Chahine, CFO of Paragon 28, reports the disposition of common stock and performance stock units due to the merger with Zimmer Biomet, where each share was converted into cash and a contingent value right.
Director Alf Grunwald reports the disposal of Paragon 28 shares following the merger with Zimmer Biomet, receiving cash and contingent value rights.
Chadi Chahine, CFO of Paragon 28, reports acquiring and disposing of common stock and holding 520,657 shares following the reported transaction.
EVP of Research & Development at Paragon 28, Andrew James Hill, reports the acquisition of restricted stock units and a decrease in holdings.
Chief Commercial Officer Matthew Jarboe reports acquisition and disposal of Paragon 28, Inc. common stock and restricted stock units.
Robert S. McCormack, General Counsel and Corporate Secretary of Paragon 28, Inc., reports the acquisition of restricted stock units and disposal of common stock.
Albert DaCosta, a director, 10% owner, and officer of Paragon 28, Inc., reported acquiring 337,682 shares of common stock on March 20, 2025, according to a Form 4 filing.
Albert DaCosta, a director, 10% owner, and officer of Paragon 28, Inc., reports changes in his beneficial ownership of the company's common stock due to gift transactions.
MVM Partners, LLC, a 10% owner of Paragon 28, Inc., sold 1,044,295 shares of common stock at a weighted average price of $13.0405 on March 13, 2025.
Robert S. McCormack, General Counsel and Corporate Secretary of Paragon 28, Inc., reports the withholding of 8,165 common stock shares to cover tax liabilities related to vesting restricted stock units on March 10, 2025.
Chief Commercial Officer Matthew Jarboe of Paragon 28, Inc. reports disposition of shares to cover tax obligations related to vesting restricted stock units.
Albert DaCosta, a director, 10% owner, and officer of Paragon 28, Inc., reported a transaction involving common stock due to tax liability from vesting restricted stock units.
MVM Partners, a significant shareholder of Paragon 28, Inc. (FNA), has sold a portion of its holdings over three days in March 2025.
Albert DaCosta, CEO of Paragon 28, Inc., disposed of 11,341 shares of common stock to cover tax liabilities related to vesting restricted stock units.
Matthew Jarboe, Chief Commercial Officer of Paragon 28, Inc., reports the disposition of 4,136 shares of common stock to cover tax liabilities related to vesting restricted stock units.
MVM Partners, LLC, a significant shareholder in Paragon 28, Inc. (FNA), has decreased its holdings through a series of stock sales in late January 2025.
MVM Partners, LLC, a significant shareholder of Paragon 28, Inc. (FNA), has sold a portion of its common stock holdings in two transactions.
Form 4: Paragon 28, Inc. Executive Albert DaCosta Reports Stock Option Exercise and Tax Liability Coverage
Albert DaCosta, a director, 10% owner, and officer of Paragon 28, Inc., exercised stock options and covered the resulting tax liability, altering his beneficial ownership in the company's stock.
Director David M Demski of Paragon 28, Inc. acquired 34,207 restricted stock units, which will vest over three years.
MVM Partners, a significant shareholder in Paragon 28, Inc., has sold a portion of its holdings in two separate transactions.
Kristina Wright, a director at Paragon 28, sold 2,360 shares of common stock at an average price of $10.001 per share under a pre-arranged 10b5-1 trading plan.